Article
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Blood - 1 Apr 2008
Roche-Lestienne Catherine, Deluche Lauréline, Corm Sélim, Tigaud Isabelle, Joha Sami, Philippe Nathalie, Geffroy Sandrine, Laï Jean-Luc, Nicolini Franck-Emmanuel, Preudhomme Claude
Abstract excerpt
Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%)...
Topics
- Acute Disease
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Benzamides
- Blast Crisis
- Chromosomes, Human
- Chronic Disease
- Core Binding Factor Alpha 2 Subunit